{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'medical judgment that the responsibility of the IMP(s) in the occurrence of the concerned event', 'was unlikely and if the selection criteria for the study are still met (refer to Section 7.1 and', 'Section 7.2).', 'For all temporary treatment discontinuations, duration must be recorded by the Investigator in the', 'appropriate pages of the e-CRF.', '10.3.2 Permanent treatment discontinuation with investigational medicinal product(s)', 'Permanent treatment discontinuation is any treatment discontinuation associated with the', 'definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at', 'any time.', '10.3.3 List of criteria for permanent treatment discontinuation', 'The patients may withdraw from treatment with the IMP if they decide to do so, at any time and', \"irrespective of the reason, or this may be the Investigator's decision. All efforts should be made to\", 'document the reason(s) for treatment discontinuation and this should be documented in the e-CRF', 'in the EOTP Visit.', 'Patients must discontinue the IMP for the following reasons:', 'Pregnancy or intention for pregnancy.', 'At patient/parents request (ie, withdrawal of the consent for treatment).', \"If, in the Investigator's opinion, continuation with the administration of the IMP would be\", \"detrimental to the patient's well-being.\", 'Intercurrent condition that requires discontinuation of the IMP (eg, laboratory', 'abnormalities, please refer to decision tree in Appendix B).', 'Life threatening events (such as such as myocardial ischemia, pulmonary alveolar', 'hemorrhage, HLH,.. )', 'At the specific request of the Sponsor.', 'Any abnormal laboratory value will be immediately repeated for confirmation (within 24 hours if', 'possible), before making a decision of permanent discontinuation of the IMP for the concerned', 'patient.', '10.3.4 Handling of patients after permanent treatment discontinuation', 'Patients will be followed-up according to the study procedures specified in this protocol up to the', 'scheduled date of study completion, or up to recovery or stabilization of any AE to be', 'followed-up as specified in this protocol, whichever comes last.', 'All cases of permanent treatment discontinuation must be recorded by the Investigator in the', 'appropriate pages of the e-CRF when considered as confirmed.', 'Property of the Sanofi Group - strictly confidential', 'Page 76', 'VV-CLIN-02544065.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '10.3.5 Procedure and consequence for patient withdrawal from study', 'The patients may withdraw from the study before study completion if they decide to do so, at any', 'time and irrespective of the reason. Withdrawal of consent for treatment should be distinguished', 'from withdrawal of consent for follow-up visits and from withdrawal of consent for nonpatient', 'contact follow-up, eg, medical records check. Patients requesting withdrawal should be informed', 'that withdrawal of consent for follow-up may jeopardize the public health value of the study.', 'If possible, the patients are assessed using the procedure normally planned for the end-of-study', 'visit.', 'Patients who withdraw should be explicitly asked about the contribution of possible AEs to their', 'decision to withdraw consent, and any AE information elicited must be documented. Preferably', \"the patient should withdraw consent in writing and, if the patient or the patient's representative\", \"refuses or is physically unavailable, the site should document and sign the reason for the patient's\", 'failure to withdraw consent in writing.', 'All study withdrawals must be recorded by the Investigator in the appropriate screens of the', \"e-CRF and in the patient's medical records when considered as confirmed. In the medical record,\", 'at least the date of the withdrawal and the reason should be documented.', 'For patients who fail to return to the site, unless the patient withdraws consent for follow-up, the', \"Investigator must make the best effort to recontact the patient (eg, contact patient's family or\", 'private physician, review available registries or health care databases), and to determine his/her', 'health status, including at least his/her vital status. Attempts to contact such patients must be', \"documented in the patient's records (eg, times and dates of attempted telephone contact, receipt\", 'for sending a registered letter).', 'The statistical analysis plan (SAP) will specify how these patients lost to follow-up for their', 'primary endpoints will be considered.', '10.4 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING', '10.4.1 Definitions of adverse events', '10.4.1.1 Adverse event', 'An AE is any untoward medical occurrence in a patient or clinical investigation patient', 'administered a pharmaceutical product and which does not necessarily have to have a causal', 'relationship with this treatment.', '10.4.1.2 Serious adverse event', 'An SAE is any untoward medical occurrence that at any dose:', 'Results in death, or,', 'Property of the Sanofi Group - strictly confidential', 'Page 77', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}